Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Busulfan in High-Risk Multiple Myeloma
NCT00113919Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Jun 2004
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Maximal Dose of Busulfex with Acceptable Toxicity at 3 years. Started Jun 2004; status: terminated.
02
Drugs
busulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00113919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113919.